Clinical Trials Logo
  1. Home
  2. Thymic Carcinoma
  3. NCT03517488

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors — DUET-2  

Hepatocellular Carcinoma Clinical Trial

Official title:
A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Clinical Trial Summary

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Anus Neoplasms
  • Basal Cell Carcinoma
  • Breast Carcinoma
  • Breast Neoplasms
  • Carcinoma
  • Carcinoma, Basal Cell
  • Carcinoma, Neuroendocrine
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Squamous Cell
  • Castration-Resistant Prostate Carcinoma
  • Cervical Cancer
  • Cholangiocarcinoma
  • Colorectal Carcinoma
  • Colorectal Neoplasms
  • Endometrial Carcinoma
  • Endometrial Neoplasms
  • Fallopian Tube Carcinoma
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • Hepatocellular Carcinoma
  • Lung Neoplasms
  • Malignant Adnexal Neoplasms
  • Melanoma
  • Mesothelioma
  • Mesothelioma, Malignant
  • Nasopharyngeal Carcinoma
  • Neuroendocrine Carcinoma
  • Non-small Cell Lung Carcinoma
  • Non-squamous Cell Salivary Gland Carcinoma
  • Ovarian Carcinoma
  • Renal Cell Carcinoma
  • Small Cell Lung Carcinoma
  • Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy
  • Squamous Cell Carcinoma of Head and Neck
  • Squamous Cell Carcinoma of the Anus
  • Squamous Cell Carcinoma of the Head and Neck
  • Squamous Cell Carcinoma of the Penis
  • Thymic Carcinoma
  • Thymoma
  • Urothelial Carcinoma
  • Uterine Cervical Neoplasms
  • Vulvar Carcinoma
  • Vulvar Neoplasms
Clinical Trial Details
NCT number NCT03517488
Study type Interventional
Source Xencor, Inc.
Contact
Status Completed
Phase Phase 1
Start date July 10, 2018
Completion date September 6, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2